Related Experiment Video
Updated: Aug 14, 2026
07:49
Slow-release Drug Delivery through Elvax 40W to the Rat Retina: Implications for the Treatment of Chronic Conditions
Published on: September 17, 2014
Eudragit S100 entrapped insulin microspheres for oral delivery
Deepti Jain1, Amulya K Panda, Dipak K Majumdar
1Department of Pharmaceutics, Delhi Institute of Pharmaceutical Sciences and Research, formerly College of Pharmacy, University of Delhi, Pushp Vihar, Sector-III, New Delhi-110017, India.
AAPS Pharmscitech
|December 16, 2005
Summary
Eudragit S100 microspheres effectively deliver insulin orally, protecting it from degradation and lowering blood glucose levels in rabbits. This research highlights their potential as oral peptide drug carriers.
Area of Science:
- Pharmaceutics
- Drug Delivery Systems
- Biomaterials
Background:
- Oral delivery of peptide drugs like insulin is challenging due to gastrointestinal degradation.
- Microsphere technology offers a potential solution for protecting sensitive drugs.
Purpose of the Study:
- To evaluate Eudragit S100 microspheres as oral carriers for insulin.
- To optimize microsphere formulation for maximum encapsulation and controlled release.
Main Methods:
- Water-in-oil-in-water emulsion solvent evaporation technique was used.
- Polyvinyl alcohol (PVA) was employed as a stabilizer.
- Insulin encapsulation efficiency, release kinetics, particle size, and in vivo hypoglycemic effect were assessed.
Main Results:
- Maximum encapsulation efficiency of 81.8% was achieved with PVA-stabilized microspheres.
- Controlled insulin release observed, following Higuchi kinetics.
- Oral administration in rabbits showed a significant reduction in blood glucose levels (up to 76%).
Conclusions:
- Eudragit S100 microspheres protect insulin from proteolytic degradation.
- These microspheres demonstrate potential for effective oral insulin delivery.
- Further research may lead to non-invasive insulin therapy options.
Related Concept Videos
01:21Intrauterine Drug Delivery Systems
Controlled-release systems for intravaginal and intrauterine drug delivery have been developed primarily for the administration of contraceptive steroid hormones. These delivery routes circumvent first-pass hepatic metabolism, thereby enhancing bioavailability and allowing for reduced systemic dosages compared to oral administration. Such approaches contribute to improved therapeutic efficacy and patient compliance, particularly in long-term contraceptive regimens.Intravaginal Drug Delivery...
01:30Production of Pharmaceuticals
Industrial insulin production uses genetically engineered E. coli expressing a proinsulin gene controlled by a tryptophan promoter and containing a methionine linker for later cleavage. The cells also carry ampicillin resistance for selective growth. Seed cultures are stored at −80 °C and production begins by thawing a small amount to inoculate starter cultures, which are progressively scaled to a 50,000-L bioreactor. In the bioreactor, E. coli grow in nutrient-rich media under sterile, tightly...
01:22Modified-Release Drug Delivery Systems: Rate-Programmed I
Rate-programmed drug delivery systems (DDS) are designed to release drugs at specific, controlled rates to maintain consistent therapeutic levels. These systems are categorized based on their release mechanisms, including dissolution-controlled DDS, diffusion-controlled DDS, and combined dissolution-diffusion-controlled DDS.In dissolution-controlled DDS, the release rate depends on the slow dissolution of the drug itself or the surrounding matrix. Drugs with inherently slow dissolution rates,...
01:27Insulin Formulations: Types and Delivery
Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into rapid-acting...
Short-acting insulins are divided into rapid-acting...
01:11Oral Drug Delivery Systems: Delayed-Release Systems
Delayed-release drug delivery systems are specialized pharmaceutical formulations designed to postpone the release of active compounds until the drug reaches a specific region of the gastrointestinal (GI) tract, typically the intestine. These systems are essential for drugs that may cause gastric irritation, are unstable in acidic environments, or need to exert therapeutic effects locally in the intestinal or colonic regions.The core feature of delayed-release systems is the use of enteric...
01:19Modified-Release Drug Delivery Systems: Rate-Programmed II
Rate-programmed drug delivery systems release drugs in a controlled manner to maintain therapeutic levels. Three main designs include reservoir, matrix, and hybrid systems.Reservoir systems consist of a drug core enclosed within a membrane that controls drug release. In non-swelling reservoir systems, polymers like ethyl cellulose or polymethacrylates are used. These do not hydrate in aqueous media and control release through membrane thickness, porosity, or insolubility. This type includes...